Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
59.66B
Market cap59.66B
Price-Earnings ratio
75.30
Price-Earnings ratio75.30
Dividend yield
3.20%
Dividend yield3.20%
Average volume
2.70M
Average volume2.70M
High today
$18.88
High today$18.88
Low today
$18.52
Low today$18.52
Open price
$18.60
Open price$18.60
Volume
1.92M
Volume1.92M
52 Week high
$18.88
52 Week high$18.88
52 Week low
$12.99
52 Week low$12.99

TAK News

TipRanks 5h
Takeda Targets Infection Risk in Multiple Myeloma With New Gammagard Phase 3 Study

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. President's Day Sale - 70% Off Unlock hedge fund-level data and powerfu...

TipRanks 5h
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda’s new post-marketing database survey tracks the real-world safe...

TipRanks 5h
Takeda’s Livmarli Safety Study in Japan: What Investors Should Watch in Rare Liver Disease

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. The study “A Cohort Study to Investigate the Risk of Liver Disorder of...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
40%
Sell
6.7%

More TAK News

TipRanks 5h
Takeda Advances Elritercept Into Phase 3, Targeting a New Edge in Anemia Care for MDS

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Multicenter, Open-Label, Randomized Tria...

Benzinga 6h
Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio....

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps
TipRanks 1d
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO

Takeda (TAK) announced data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO can offer the possibility of clinical remission for patients...

TipRanks 2d
Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda (TAK) is launching a Phase 2 trial titled “A Phase 2, Randomize...

TipRanks 2d
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is running a prospective, observational study called “A Prospec...

TipRanks 2d
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda (TAK) is backing a new diagnostic study for hereditary angioede...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.